Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs; ≥52 weeks) was performed and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is evidence for acceptable safety for use up to 52 weeks.1821”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1821]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma
Program, P., & theDiagnosis, T. E. P. O. (1997) · Cited by 4,926
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Omalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
Hanania, N. A., Alpan, O., Hamilos, D. L., Condemi, J. J., Reyes-Rivera, I., Zhu, J., Rosen, K. E., Eisner, M. D., Wong, D. A., & Busse, W. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00002 · Cited by 554
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Holgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1916.x · Cited by 522
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M., & Cioppa, G. D. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00770.x · Cited by 401
The Role of Immunoglobulin E in Allergy and Asthma
PLATTS-MILLS, T. A. E. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.supplement_1.2103024 · Cited by 362
Lanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.021 · Cited by 360
Predicting and evaluating response to omalizumab in patients with severe allergic asthma
Bousquet, J., Rabe, K., Humbert, M., Chung, K. F., Berger, W., Fox, H., Ayre, G., Chen, H., Thomas, K., Blogg, M., et al. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.01.011 · Cited by 304
Ayres, J. G., Higgins, B., Chilvers, E. R., Ayre, G., Blogg, M., & Fox, H. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00533.x · Cited by 279 · cited 1×
“Specific inclusion criteria were as follows: (1) adults/adolescents (12 years or older) and children (aged between 6 and 12 years) with a diagnosis of persistent uncontrolled moderate to severe allergic asthma in spite of high-dose ICS or ICS plus LABAs, (2) investigations of patients who received subcutaneous omalizu…”
MethodPredicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma
Bousquet, J., Wenzel, S., Holgate, S., Lumry, W., Freeman, P., & Fox, H. (2004) · Chest · doi:10.1378/chest.125.4.1378 · Cited by 277
Rodrigo, G. J., Neffen, H., & Castro-Rodriguez, J. A. (2011) · Chest · doi:10.1378/chest.10-1194 · Cited by 268
Peters, S. P., Jones, C. A., Haselkorn, T., Mink, D. R., Valacer, D. J., & Weiss, S. T. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.022 · Cited by 252
Safety and tolerability of omalizumab
Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., & Jimenez, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03214.x · Cited by 252
Anti-IgE for chronic asthma in adults and children
Walker, S., Monteil, M., Phelan, K., Lasserson, T. J., & Walters, E. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub3 · Cited by 236
Massanari, M., Nelson, H., Casale, T., Busse, W., Kianifard, F., Geba, G. P., & Zeldin, R. K. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.022 · Cited by 230
Omalizumab is effective in the long-term control of severe allergic asthma
Lanier, B. Q., Corren, J., Lumry, W., Liu, J., Fowler-Taylor, A., & Gupta, N. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62170-9 · Cited by 183
Berger, W., Gupta, N., McAlary, M., & Fowler-Taylor, A. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62175-8 · Cited by 182
Hochhaus, G., Brookman, L., Fox, H., Johnson, C., Matthews, J., Ren, S., & Deniz, Y. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002171 · Cited by 181
Kopp, M. V., Hamelmann, E., Zielen, S., Kamin, W., Bergmann, K. ‐., Sieder, C., Stenglein, S., Seyfried, S., Wahn, U., & for the DUAL study group (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03121.x · Cited by 181
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Buhl, R., Solèr, M., Matz, J., Townley, R., O'Brien, J., Noga, O., Champain, K., Fox, H., Thirlwell, J., & Della Cioppa, G. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00278102 · Cited by 179
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma
Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., Fowler-Taylor, A., Liu, J., & Gupta, N. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.54 · Cited by 173
Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab
Noga, O., Hanf, G., & Kunkel, G. (2003) · International Archives of Allergy and Immunology · doi:10.1159/000070434 · Cited by 168
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
Bousquet, J., Siergiejko, Z., Świebocka, E., Humbert, M., Rabe, K. F., Smith, N., Leo, J., Peckitt, C., Maykut, R., & Peachey, G. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02522.x · Cited by 168
Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma
Hoshino, M., & Ohtawa, J. (2012) · Respiration · doi:10.1159/000334701 · Cited by 164
Buhl, R., Hanf, G., Solèr, M., Bensch, G., Wolfe, J., Everhard, F., Champain, K., Fox, H., & Thirlwell, J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00016502 · Cited by 160
Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma
Lemanske, R. F., Nayak, A., McAlary, M., Everhard, F., Fowler-Taylor, A., & Gupta, N. (2002) · Pediatrics · doi:10.1542/peds.110.5.e55 · Cited by 150
Oba, Y., & Salzman, G. A. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.05.049 · Cited by 142
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
Wu, A. C., Paltiel, A. D., Kuntz, K. M., Weiss, S. T., & Fuhlbrigge, A. L. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.07.055 · Cited by 117
Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma
Brown, R., Turk, F., Dale, P., & Bousquet, J. (2007) · Allergy · doi:10.1111/j.1398-9995.2006.01310.x · Cited by 112
Norman, G., Faria, R., Paton, F., Llewellyn, A., Fox, D., Palmer, S., Clifton, I., Paton, J. Y., Woolacott, N. F., & McKenna, C. (2013) · Health Technology Assessment · doi:10.3310/hta17520 · Cited by 107
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
Kulus, M., Hébert, J., García, E., Taylor, A. F., Vidaurre, C. F., & Blogg, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003771338 · Cited by 102
Dewilde, S., Turk, F., Tambour, M., & Sandström, T. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132389 · Cited by 94
Silkoff, P. E., Romero, F. A., Gupta, N., Townley, R. G., & Milgrom, H. (2004) · PEDIATRICS · doi:10.1542/peds.113.4.e308 · Cited by 91
Efficacy and safety of omalizumab in an Asian population with moderate‐to‐severe persistent asthma
Ohta, K., Miyamoto, T., Amagasaki, T., Yamamoto, M., & on behalf of the 1304 Study Group (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01633.x · Cited by 90
Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients
Siergiejko, Z., Świebocka, E., Smith, N., Peckitt, C., Leo, J., Peachey, G., & Maykut, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.620950 · Cited by 89
Omalizumab-induced decrease of FcɛRI expression in patients with severe allergic asthma
Chanez, P., Contin‐Bordes, C., Garcia, G., Verkindre, C., Didier, A. P., Frederic de, B. L. A. Y., de Lara, M. T., Blanco, P., Moreau, J., Robinson, P., et al. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.07.011 · Cited by 88
Niven, R. M., Chung, K. F., Panahloo, Z., Blogg, M., & Ayre, G. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.06.002 · Cited by 88
The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective
Campbell, J. D., Spackman, E., & Sullivan, S. D. (2010) · Allergy · doi:10.1111/j.1398-9995.2010.02336.x · Cited by 87
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2012) · Survey of Anesthesiology · doi:10.1097/01.sa.0000410631.09026.a4 · Cited by 87
Almonds Have a Neutral Effect on Serum Lipid Profiles: A Meta-Analysis of Randomized Trials
Phung, O. J., Makanji, S. S., White, C. M., & Coleman, C. I. (2009) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2009.02.014 · Cited by 76
Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma
Milgrom, H., FowlerTaylor, A., Vidaurre, C. F., & Jayawardene, S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.539502 · Cited by 73
An evaluation of the cost‐effectiveness of omalizumab for the treatment of severe allergic asthma
Sullivan, S. D., & Turk, F. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01723.x · Cited by 71
Li, Z., & Begg, C. B. (1994) · Journal of the American Statistical Association · doi:10.1080/01621459.1994.10476892 · Cited by 66
Bardelas, J. A., Figliomeni, M., Kianifard, F., & Meng, X. (2012) · Journal of Asthma · doi:10.3109/02770903.2011.648296 · Cited by 60
Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands
van Nooten, F., Stern, S., Braunstahl, G.-J., Thompson, C., Groot, M., & Brown, R. E. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.756398 · Cited by 52
Improvement in quality of life with omalizumab in patients with severe allergic asthma
Chipps, B. E., Buhl, R., Beeh, K.-M., Fox, H., Thomas, K., & Reisner, C. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148643 · Cited by 51
Rubin, A. S., Souza‐Machado, A., Andradre-Lima, M., Ferreira, F. N. H., Honda, A., Matozo, T. M., & On behalf of the QUALITX Study Investigators (2012) · Journal of Asthma · doi:10.3109/02770903.2012.660297 · Cited by 48
Zielen, S., Lieb, A., Motte, S. D. L., Wagner, F. D., de Monchy, J., Fuhr, R., Munzu, C., Koehne‐Voss, S., Rivière, G., Kaiser, G., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000339243 · Cited by 46
Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma
Niebauer, K., Dewilde, S., Fox-Rushby, J. A., & Revicki, D. A. (2006) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61242-2 · Cited by 45
Let-7a is differentially expressed in bronchial biopsies of patients with severe asthma
Rijavec, M., Korošec, P., Žavbi, M., Kern, I., & Malovrh, M. M. (2014) · Scientific Reports · doi:10.1038/srep06103 · Cited by 38 · cited 3×
“Specific inclusion criteria were as follows: (1) adults/adolescents (12 years or older) and children (aged between 6 and 12 years) with a diagnosis of persistent uncontrolled moderate to severe allergic asthma in spite of high-dose ICS or ICS plus LABAs, (2) investigations of patients who received subcutaneous omalizu…”
MethodCost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy.
Negro, R. W. D., Pradelli, L., Tognella, S., Micheletto, C., & Iannazzo, S. (2011) · PubMed · Cited by 35
Vieira, T., de Oliveira, J. F., & Castel-Branco, M. G. (2012) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2012.07.006 · Cited by 31
Karpel, J. P., Massanari, M. J., Geba, G. P., Kianifard, F., Inhaber, N., & Zeldin, R. K. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.09.011 · Cited by 24
Omalizumab: An update on efficacy and safety in moderate-to-severe allergic asthma
Chipps, B. E., Figliomeni, M., & Spector, S. L. (2012) · Allergy and Asthma Proceedings · doi:10.2500/aap.2012.33.3599 · Cited by 21
Anti-Immunoglobulin E Therapy for Asthma
Owen, C. E. (2002) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.2002.0372 · Cited by 15
Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Massanari, M. J., Kianifard, F., Zeldin, R. K., & Geba, G. P. (2009) · Allergy and Asthma Proceedings · doi:10.2500/aap.2009.30.3245 · Cited by 13
Luskin, A. T., Kosinski, M. R., Bresnahan, B. W., Ashby, M. A., & Wong, D. A. (2005) · Journal of Asthma · doi:10.1080/02770900500369868 · Cited by 12
Research works printed but not linked: 3
- National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. <http://www.ncbi.nlm.nih.gov/books/NBK7232/> (2007) Date of access: 20/07/2014.
- Bardelas, J., Figliomeni, M., Kianifard, F. & Meng, X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 49, 44–52 (2012). · DOI
- Lanier, B. Q. et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91,154–159 (2003). · DOI · Paper page
Cited by
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Gevaert, P., Omachi, T. A., Corren, J., Mullol, J., Han, J., Lee, S. E., Kaufman, D., Ligueros-Saylan, M., Howard, M., Zhu, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.032 · Cited by 739
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Asthma phenotypes and IgE responses
Froidure, A., Mouthuy, J., Durham, S. R., Chanez, P., Sibille, Y., & Pilette, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.01824-2014 · Cited by 267
Li, J., Fan, L., Li, M.-H., Cao, W.-J., & Xu, J. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.019 · Cited by 130
Asthma biomarkers in the age of biologics
Kim, H. L., Ellis, A. K., Fischer, D., Noseworthy, M., Olivenstein, R., Chapman, K. R., & Lee, J. (2017) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-017-0219-4 · Cited by 125
“Initial trials demonstrating the safety and effectiveness of omalizumab in the management of moderate to severe allergic asthma [18–23] are supported by long-term (≥ 52 weeks) and real-world studies [188–191] and more than 400,000 patient-years of experience [192].”
Background
Metadata
- Authors
- Lai, T., Wang, S., Xu, Z., Zhang, C., Zhao, Y., Hu, Y., Cao, C., Ying, S., Chen, Z., Li, W., Wu, B., & Shen, H.
- Affiliations
- Guangdong Medical College (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Corresponding author
- Wu, Bin
- Shen, Huahao
- ORCID
- Venue
- Scientific Reports
- Published
- 2015-02-03
- Volume
- 5
- Issue
- 1
- Pages
- 8191-8191
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4314644
- OpenAlex
- W2019947521
- Cited by
- 103
- References
- 68
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 14 · 2019: 14 · 2018: 19 · 2017: 15 · 2016: 12 · 2015: 4
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-08-14)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81370126, 2012BAI05B01)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- omalizumab, allergic asthma, long-term efficacy, drug safety, asthma exacerbations, inhaled corticosteroid withdrawal, quality of life, cost-effectiveness, anti-IgE therapy
- MeSH terms
- Omalizumab, Age Factors, Asthma, Clinical Trials as Topic, Humans, Severity of Illness Index, Databases, Factual, Treatment Outcome, Anti-Allergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


